Insight from Proactive analyst Ed Stacey on Mydecine Innovations Group, a biotech and life sciences company which is developing new therapies derived from psychedelics including psilocybin from mushrooms.
Proactive Analyst Ed Stacey looks at Mydecine Innovations
Quick facts: Mydecine Innovations Group Inc
Price: 0.303 USD
Market Cap: $72.32 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE